MedTrace Logo

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00005787 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2012-06-01

No results posted yet for this study

Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Treating the peripheral stem cells in the laboratory may improve the effectiveness of the transplant.

PURPOSE: Phase I trial to study the effectiveness of peripheral stem cell transplantation in patients who have relapsed or refractory non-Hodgkin's lymphoma and who will be treated with high-dose chemotherapy.

Conditions

Interventions

BIOLOGICAL

epoetin alfa

BIOLOGICAL

filgrastim

BIOLOGICAL

recombinant flt3 ligand

BIOLOGICAL

recombinant interleukin-3

BIOLOGICAL

sargramostim

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Jane N. Winter, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
17 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2002-01-31
Completion
2002-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005787 on ClinicalTrials.gov